Spectrum Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-06-2024
- Paid Up Capital ₹ 56.50 K
as on 27-06-2024
- Company Age 46 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -20.12%
(FY 2020)
- Profit -406.74%
(FY 2020)
- Ebitda -210.79%
(FY 2020)
- Net Worth -7.09%
(FY 2020)
- Total Assets -6.08%
(FY 2020)
About Spectrum Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 56.50 K , as per Ministry of Corporate Affairs (MCA) records.
Anil Dumbre and Laxman Ufale serve as directors at the Company.
- CIN/LLPIN
U24230MH1978PTC020535
- Company No.
020535
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 1978
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Spectrum Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Dumbre  | Director | 14-Jul-2022 | Current |
| Laxman Ufale | Additional Director | Current |
Financial Performance of Spectrum Pharmaceuticals.
Spectrum Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 20.12% decrease. The company also saw a substantial fall in profitability, with a 406.74% decrease in profit. The company's net worth dipped by a decrease of 7.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Spectrum Pharmaceuticals?
In 2020, Spectrum Pharmaceuticals had a promoter holding of 100.00%. The company had 2 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Amaysr Laboratories Private LimitedActive 5 years 26 daysAnil Dumbre and Laxman Ufale are mutual person
- Krisp Laboratories Private LimitedActive 38 years 5 months
Anil Dumbre and Laxman Ufale are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a workforce of 56 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Spectrum Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Spectrum Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
